Zacks Company Profile for Vyant Bio, Inc. (VYNT : NSDQ) |
|
|
|
Company Description |
VYANT BIO INC. operates through wholly-owned subsidiaries, StemoniX and vivoPharm. StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. VYANT BIO INC., formerly known as Cancer Genetics Inc., is based in CHERRY HILL, N.J.
Number of Employees: 34 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $0.68 |
Daily Weekly Monthly
 |
20 Day Moving Average: 50,380 shares |
Shares Outstanding: 29.41 (millions) |
Market Capitalization: $19.85 (millions) |
Beta: 2.31 |
52 Week High: $4.24 |
52 Week Low: $0.64 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-35.10% |
-28.88% |
12 Week |
-38.91% |
-33.72% |
Year To Date |
-50.00% |
-40.54% |
|
|
|
|
|
Address & Contact Information |
Street Address |
Phone / Fax |
Email Address |
Web URL |
2 Executive Campus 2370 State Route 70 Suite 310 - Cherry Hill,NJ 08002 USA |
ph: 201-479-8126 fax: 201-528-9201 |
jzimmons@zimmonsic.com |
http://www.vyantbio.com |
|
|
|
General Corporate Information |
Officers
John A. Roberts - Chief Executive Officer and President
John Fletcher - Chairman of the Board of Directors
Andrew D.C. LaFrence - Chief Financial Officer
Geoffrey Harris - Director
Yung-Ping Yeh - Director
|
|
Peer Information
Vyant Bio, Inc. (CORR.)
Vyant Bio, Inc. (RSPI)
Vyant Bio, Inc. (CGXP)
Vyant Bio, Inc. (BGEN)
Vyant Bio, Inc. (GTBP)
Vyant Bio, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92942V109
SIC: 8071
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
|
|
Share - Related Items
Shares Outstanding: 29.41
Most Recent Split Date: 10.00 (0.03:1)
Beta: 2.31
Market Capitalization: $19.85 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $-0.15 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-0.67 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 08/15/22 |
|
|
|
|